^
    Back
    Association details:
    Biomarker:MSI-H/dMMR
    Cancer:Gastroesophageal Junction Adenocarcinoma
    Drug:Imfinzi (durvalumab) (PD-L1 inhibitor) +
    Imjudo (tremelimumab) (CTLA4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    08/29/2023
    Excerpt:
    Esophageal and Esophagogastric Junction Cancers: Useful in Certain Circumstances…MSI-H/dMMR tumors…Tremelimumab and durvalumab for neoadjuvant therapy only…
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO-GI 2023
    Title:

    INFINITY: A multicentre, single-arm, multi-cohort, phase II trial of tremelimumab and durvalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC).

    Published date:
    01/17/2023
    Excerpt:
    Overall, 18 pts with MSI/dMMR resectable cT2-4 any N GAC/GEJAC were recruited in Cohort 1….Among 15 evaluable patients, 1 had disease progression and 14 underwent resection. pCR rate was 60% (9/15) and major-complete pathological response (<10% viable cells) was 80%....Pre-operative T300/D for 3 months was safe and provided promising proof of efficacy in MSI, dMMR GAC/GEJAC pts.
    DOI:
    10.1200/JCO.2023.41.3_suppl.358
    Trial ID:
    INFINITY